Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone

MONARK is a pilot randomized trial comparing the safety and efficacy of lopinavir/ritonavir (LPV/r) monotherapy to a standard triple-drug regimen as initial therapy. The primary endpoint was virological response (VR) defined as viral load (VL)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral therapy 2009, Vol.14 (1), p.93-97
Hauptverfasser:	FLANDRE, Philippe, DELAUGERRE, Constance, ROUZIOUX, Christine, DELFRAISSY, Jean-Francois, GHOSN, Jade, LAURE CHAIX, Marie, HORBAN, Andrzej, GIRARD, Pierre-Marie, GLADYSZ, Andrzej, COHEN-CODAR, Isabelle, NGO VAN, Philippe, TABURET, Anne-Marie
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Drug Therapy, Combination HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - virology HIV Protease Inhibitors - administration & dosage HIV-1 - drug effects HIV-1 - genetics Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Lopinavir Medical sciences Medication Adherence Pharmacology. Drug treatments Pilot Projects Predictive Value of Tests Prognosis Pyrimidinones - administration & dosage Ritonavir - administration & dosage RNA, Viral - analysis RNA, Viral - drug effects Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	MONARK is a pilot randomized trial comparing the safety and efficacy of lopinavir/ritonavir (LPV/r) monotherapy to a standard triple-drug regimen as initial therapy. The primary endpoint was virological response (VR) defined as viral load (VL)
ISSN:	1359-6535 2040-2058
DOI:	10.1177/135965350901400105